ValiRx PLC NOTIFICATION OF AUSTRALIAN PATENT ALLOWANCE (0240G)
24 May 2017 - 4:00PM
UK Regulatory
TIDMVAL
RNS Number : 0240G
ValiRx PLC
24 May 2017
ValiRx Plc
("ValiRx" or the "Company")
NOTIFICATION OF AUSTRALIAN PATENT ALLOWANCE FOR THERAPEUTIC
COMPOUND, VAL401
London, UK., 24 May 2017: ValiRx Plc (AIM: VAL), the clinical
stage biotechnology company, is pleased to report that ValiSeek
Limited ("ValiSeek"), the joint venture between ValiRx and Tangent
Reprofiling Limited ("Tangent"), has received notification, that an
Australian patent covering VAL401 and its use in the treatment of
cancer, has been allowed by the Australian Patent Office.
ValiSeek was formed to progress VAL401 into Clinical trials for
the treatment of lung cancer and other oncology indications.
The allowance of this latest patent means that ValiSeek now has
patent protection for VAL401 in New Zealand, Australia and
previously announced patents in the United States. There are also
further patents pending for the compound in significant markets
across the rest of the world, alongside other granted and patents
pending for the Group's therapeutic technologies world-wide.
The directors of ValiSeek are pleased to receive this
notification of allowance for this patent, further strengthening
ValiSeek's portfolio at an important time in VAL401's development
pathway.
This announcement contains inside information for the purposes
of Article 7 of EU Regulation 596/2014.
*** ENDS ***
For more information, please contact:
ValiRx plc Tel: +44 (0) 20
3008 4416
www.valirx.com
Dr Satu Vainikka, Chief Executive Tel: +44 (0) 20
3008 4416
Tarquin Edwards, Head of Communications. Tel: +44 (0) 7879
458 364
tarquin.edwards@valirx.com
Cairn Financial Advisers LLP Tel: +44 (0) 20
(Nominated Adviser) 7213 0880
Liam Murray/Jo Turner/Richard
Nash
Beaufort Securities Limited Tel: +44 (0) 207
(Broker) 382 8300
Jon Belliss
Notes for Editors
About ValiSeek
ValiSeek Limited ("ValiSeek") is a joint venture ("JV") company
between ValiRx Plc and Tangent Reprofiling Limited, part of the
SEEK Group. ValiSeek was formed to progress the drug VAL401 through
its remaining preclinical development and towards Phase II trials
for the treatment of lung cancer and other oncology
indications.
About ValiRx
ValiRx is a biotechnology oncology focused company specialising
in developing novel treatments for cancer and associated
biomarkers. It aims to make a significant contribution in
"precision" medicine and science, namely to engineer a breakthrough
into human health and well-being, through the early detection of
cancer and its therapeutic intervention.
The Company's business model focuses on out-licensing
therapeutic candidates early in the development process. By aiming
for early-stage value creation, the company reduces risk
considerably while increasing the potential for realising value.
The group is already in licensing discussions with major players in
the oncology field.
ValiRx's two classes of drugs in development, which each have
the potential for meeting hitherto unmet medical needs by existing
methods, have worldwide patent filings and agreed commercial
rights. They originate or derive from Word class institutions, such
as Cancer Research UK and Imperial College.
Until recently, cancer treatments relied on non-specific agents,
such as chemotherapy. With the development of target-based agents,
primed to attack cancer cells only, less toxic and more effective
treatments are now possible. New drugs in this group-such as those
in ValiRx's pipeline-promise to greatly improve outcomes for cancer
patients.
The Company listed on the AIM Market of the London Stock
Exchange in October 2006 and trades under the ticker symbol:
VAL.
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCSEDFMDFWSESI
(END) Dow Jones Newswires
May 24, 2017 02:00 ET (06:00 GMT)
Valirx (LSE:VAL)
Historical Stock Chart
From Apr 2024 to May 2024
Valirx (LSE:VAL)
Historical Stock Chart
From May 2023 to May 2024